ClinicalTrials.Veeva

Menu

Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients

Boehringer Ingelheim logo

Boehringer Ingelheim

Status

Completed

Conditions

Hypertension

Treatments

Drug: Telmisartan or Telmisartan and Hydrochlorthiazide

Study type

Observational

Funder types

Industry

Identifiers

NCT01108809
502.592

Details and patient eligibility

About

The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risk scores. The study will also evaluate the current antihypertensive treatment pattern in the daily practice among the patient population at increased cardiovascular risk.

Enrollment

295 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • diagnosis of essential arterial hypertension (BP>140/90 mm HG or BP>130/80 mm Hg for diabetic patients)
  • at least one additional cardiovascular risk factor and/or known single or multiple end organ damage and/or previous cardiovascular disease

Exclusion criteria

  • hypersensitivity to the active substance or to any of the excipients in any ACE inhibitor or angiotensin receptor blocker (ARB) available on the local market, as prescribed in the SPC
  • pregnancy and lactation
  • diseases involving biliary obstruction
  • severe liver impairment
  • severe hypertension
  • malignant hypertension
  • secondary hypertension
  • patients age under 18 years

Trial design

295 participants in 1 patient group

Patients with arterial hypertension
Treatment:
Drug: Telmisartan or Telmisartan and Hydrochlorthiazide

Trial contacts and locations

49

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems